Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$52.76
+0.1%		$50.77
$39.41
▼
$88.24
$9.20B1.152.24 million shs357,483 shs
BXP, Inc. stock logo
BXP
BXP
$68.03
-0.3%		$68.66
$49.72
▼
$79.33
$10.87B1.011.92 million shs352,288 shs
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$29.22
-0.1%		$30.42
$21.03
▼
$32.95
$4.81B1.171.91 million shs299,858 shs
Moderna, Inc. stock logo
MRNA
Moderna
$146.24
-1.8%		$84.18
$22.28
▼
$176.66
$58.44B1.111.62 million shs10.88 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
-0.05%+0.71%+7.27%+2.70%-35.40%
BXP, Inc. stock logo
BXP
BXP
+1.61%-2.63%-3.55%+9.46%-7.49%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
+1.16%-1.11%-5.66%+5.45%+0.11%
Moderna, Inc. stock logo
MRNA
Moderna
-1.29%+4.27%+160.83%+213.81%+519.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$52.76
+0.1%		$50.77
$39.41
▼
$88.24
$9.20B1.152.24 million shs357,483 shs
BXP, Inc. stock logo
BXP
BXP
$68.03
-0.3%		$68.66
$49.72
▼
$79.33
$10.87B1.011.92 million shs352,288 shs
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$29.22
-0.1%		$30.42
$21.03
▼
$32.95
$4.81B1.171.91 million shs299,858 shs
Moderna, Inc. stock logo
MRNA
Moderna
$146.24
-1.8%		$84.18
$22.28
▼
$176.66
$58.44B1.111.62 million shs10.88 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
-0.05%+0.71%+7.27%+2.70%-35.40%
BXP, Inc. stock logo
BXP
BXP
+1.61%-2.63%-3.55%+9.46%-7.49%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
+1.16%-1.11%-5.66%+5.45%+0.11%
Moderna, Inc. stock logo
MRNA
Moderna
-1.29%+4.27%+160.83%+213.81%+519.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
1.94
Reduce$52.850.16% Upside
BXP, Inc. stock logo
BXP
BXP
2.55
Moderate Buy$75.0510.32% Upside
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
2.70
Moderate Buy$31.096.42% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-47.54% Downside

Current Analyst Ratings Breakdown

Latest ARE, MRNA, BXP, and CUZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
9/1/2026
BXP, Inc. stock logo
BXP
BXP
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$77.00 ➝ $82.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/27/2026
BXP, Inc. stock logo
BXP
BXP
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$90.00 ➝ $88.00
8/25/2026
BXP, Inc. stock logo
BXP
BXP
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$61.00 ➝ $70.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$3.03B3.04N/AN/A$109.99 per share0.48
BXP, Inc. stock logo
BXP
BXP
$3.48B3.12$8.29 per share8.21$48.41 per share1.41
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$993.82M4.84$2.78 per share10.52$27.29 per share1.07
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B30.03N/AN/A$16.93 per share8.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
-$1.43B-$6.06N/A9.94N/A-36.08%-5.21%-2.92%10/26/2026 (Estimated)
BXP, Inc. stock logo
BXP
BXP
$276.80M$1.8636.599.532.518.44%3.88%1.16%10/27/2026 (Estimated)
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$40.50M$0.04730.569.551.890.62%0.14%0.07%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest ARE, MRNA, BXP, and CUZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$0.0939-$0.43-$0.5239-$0.43$464.86 million$662.78 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$0.74$0.16-$0.58$0.16$263.55 million$268.53 million
7/28/2026Q2 2026
BXP, Inc. stock logo
BXP
BXP
$0.4031$0.43+$0.0269$0.43$858.07 million$895.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$2.885.46%+1.99%N/A 15 Years
BXP, Inc. stock logo
BXP
BXP
$2.804.12%-3.04%150.54%N/A
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
$1.284.38%-2.99%3,200.00%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ARE, MRNA, BXP, and CUZ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/31/2026
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
quarterly$0.725.59%9/30/20269/30/202610/15/2026
6/17/2026
BXP, Inc. stock logo
BXP
BXP
quarterly$0.704.22%6/30/20266/30/20267/31/2026
6/18/2026
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
quarterly$0.324.18%7/6/20267/6/20267/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
0.67
0.19
0.19
BXP, Inc. stock logo
BXP
BXP
2.07
3.91
3.91
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
0.83
1.01
1.01
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
96.54%
BXP, Inc. stock logo
BXP
BXP
98.72%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
94.38%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
1.35%
BXP, Inc. stock logo
BXP
BXP
1.50%
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
1.81%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
590174.25 million171.90 millionOptionable
BXP, Inc. stock logo
BXP
BXP
780159.66 million157.27 millionOptionable
Cousins Properties Incorporated stock logo
CUZ
Cousins Properties
256,131164.60 million161.62 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Healthcare Stocks To Watch Today - September 4th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-healthcare-stocks-to-watch-today-september-4th-2026-09-04/
Biotech Stocks To Watch Today - September 4th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-watch-today-september-4th-2026-09-04/
Insider Selling: Moderna (NASDAQ:MRNA) Insider Sells 3,471 Shares of Stock
September 4 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mrna-insider-buying-and-selling-2026-09-04/
Best Healthcare Stocks To Research - September 1st
September 4 at 4:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003305
Moderna Q3 EPS Increased by Brookline Capital Markets
September 4 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31002001
Why Moderna (MRNA) Stock Is Down Today
September 3 at 12:57 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-moderna-mrna-stock-down-013518610.html
Why Moderna (MRNA) stock is down today
September 3 at 7:57 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-moderna-mrna-stock-is-down-today/ar-AA2bwaN0
Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets
September 3 at 5:22 PM  |  fxempire.comF
Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock
September 3 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-moderna-nasdaq-mrna-insider-sells-48576645-in-stock-2026-09-03/
Moderna slips as Rothschild issues rare sell rating after cancer vaccine-led rally
September 3 at 2:56 PM  |  msn.comhttps://www.msn.com/en-us/news/other/moderna-slips-as-rothschild-issues-rare-sell-rating-after-cancer-vaccine-led-rally/ar-AA2bvXD7
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
September 3 at 2:56 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/fund-bought-moderna-nearly-tripled-144452535.html
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
September 3 at 2:56 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-modernas-mrna-flu-shot-162400177.html
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
September 3 at 1:26 PM  |  zacks.comhttps://www.zacks.com/stock/news/2984713/does-moderna-s-mrna-flu-shot-face-a-new-challenge-from-gsk?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2984713
Biotech Stocks To Follow Now - September 3rd
September 3 at 12:02 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-follow-now-september-3rd-2026-09-03/
Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating
September 3 at 11:10 AM  |  barrons.comhttps://www.barrons.com/articles/moderna-stock-cancer-vaccine-sell-rating-bdcb2ced
Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade
September 3 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-shares-gap-down-on-analyst-downgrade-2026-09-03/
Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
September 3 at 9:55 AM  |  cnbc.comhttps://www.cnbc.com/2026/09/03/moderna-is-now-overvalued-after-cancer-vaccine-led-stock-surge-rothschild-co-says.html
Rothschild & Co Redburn Downgrades Moderna (NASDAQ:MRNA) to Sell
September 3 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rothschild-co-redburn-downgrades-moderna-nasdaq-mrna-to-sell-2026-09-03/
Moderna: Massive Asymmetry About What The mRNA Is!
September 3 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4942693-moderna-massive-asymmetry-about-what-the-mrna-is
Stock Traders Purchase Large Volume of Call Options on Moderna (NASDAQ:MRNA)
September 3 at 5:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001564
Top Healthcare Stocks To Watch Now - August 31st
September 3 at 3:04 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000223

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
Belden logo displayed with networking cables, connectors, and server hardware in a dark data center setting.
The AI Boom Is Turning This Cable Maker Into a Stock to Watch
By Peter Frank | August 18, 2026
Server racks in a data center aisle with an overlaid digital network graphic and cloud icons above.
3 of the Market's Most-Upgraded Tech Stocks Right Now
By Ryan Hasson | August 10, 2026
Williams Sonoma circular logo sign on a wall surrounded by kitchenware, bowls, a pepper mill, and cutting board.
Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
By Thomas Hughes | August 26, 2026
Alexandria Real Estate Equities stock logo

Alexandria Real Estate Equities NYSE:ARE

$52.76 +0.07 (+0.13%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

BXP stock logo

BXP NYSE:BXP

$68.03 -0.20 (-0.29%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.

Cousins Properties stock logo

Cousins Properties NYSE:CUZ

$29.22 -0.04 (-0.12%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cousins Properties Incorporated ("Cousins") is a fully integrated, self-administered, and self-managed real estate investment trust (REIT). The Company, based in Atlanta and acting through its operating partnership, Cousins Properties LP, primarily invests in Class A office buildings located in high-growth Sun Belt markets. Founded in 1958, Cousins creates shareholder value through its extensive expertise in the development, acquisition, leasing, and management of high-quality real estate assets. The Company has a comprehensive strategy in place based on a simple platform, trophy assets, and opportunistic investments.

Moderna stock logo

Moderna NASDAQ:MRNA

$146.24 -2.63 (-1.77%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas